PL1824472T3 - Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii - Google Patents

Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii

Info

Publication number
PL1824472T3
PL1824472T3 PL05807584T PL05807584T PL1824472T3 PL 1824472 T3 PL1824472 T3 PL 1824472T3 PL 05807584 T PL05807584 T PL 05807584T PL 05807584 T PL05807584 T PL 05807584T PL 1824472 T3 PL1824472 T3 PL 1824472T3
Authority
PL
Poland
Prior art keywords
carnitine
acetyl
treatment
fibromyalgic syndrome
fibromyalgic
Prior art date
Application number
PL05807584T
Other languages
English (en)
Polish (pl)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PL1824472T3 publication Critical patent/PL1824472T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
PL05807584T 2004-12-13 2005-11-10 Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii PL1824472T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000606A ITRM20040606A1 (it) 2004-12-13 2004-12-13 Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
EP05807584A EP1824472B1 (en) 2004-12-13 2005-11-10 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome
PCT/EP2005/012054 WO2006063639A1 (en) 2004-12-13 2005-11-10 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome

Publications (1)

Publication Number Publication Date
PL1824472T3 true PL1824472T3 (pl) 2009-05-29

Family

ID=35708966

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05807584T PL1824472T3 (pl) 2004-12-13 2005-11-10 Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii

Country Status (16)

Country Link
US (1) US8013016B2 (enExample)
EP (1) EP1824472B1 (enExample)
JP (1) JP5057990B2 (enExample)
KR (1) KR101240182B1 (enExample)
AT (1) ATE419847T1 (enExample)
CA (1) CA2585560C (enExample)
CY (1) CY1110576T1 (enExample)
DE (1) DE602005012317D1 (enExample)
DK (1) DK1824472T3 (enExample)
ES (1) ES2320788T3 (enExample)
IT (1) ITRM20040606A1 (enExample)
MX (1) MX2007006954A (enExample)
PL (1) PL1824472T3 (enExample)
PT (1) PT1824472E (enExample)
SI (1) SI1824472T1 (enExample)
WO (1) WO2006063639A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840363A1 (en) * 2011-06-24 2012-12-27 K-Pax Pharmaceuticals, Inc. Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
ES2962933T3 (es) 2020-12-14 2024-03-21 Ims Gear Se & Co Kgaa Procedimiento para la corrección de una señal de medición dependiente del tiempo de una unidad de motor-engranaje, así como procedimiento para detectar desgaste y/o un deterioro de la misma mediante este procedimiento de corrección

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5935949A (en) * 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
ITRM20010293A1 (it) 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
KR101027570B1 (ko) * 2002-05-03 2011-04-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물

Also Published As

Publication number Publication date
EP1824472B1 (en) 2009-01-07
ITRM20040606A1 (it) 2005-03-13
JP5057990B2 (ja) 2012-10-24
ATE419847T1 (de) 2009-01-15
US20090076146A1 (en) 2009-03-19
KR101240182B1 (ko) 2013-03-07
KR20070091317A (ko) 2007-09-10
CY1110576T1 (el) 2015-04-29
CA2585560C (en) 2013-01-08
SI1824472T1 (sl) 2009-04-30
ES2320788T3 (es) 2009-05-28
MX2007006954A (es) 2007-08-02
EP1824472A1 (en) 2007-08-29
CA2585560A1 (en) 2006-06-22
WO2006063639A1 (en) 2006-06-22
DK1824472T3 (da) 2009-03-30
JP2008534433A (ja) 2008-08-28
PT1824472E (pt) 2009-03-31
DE602005012317D1 (de) 2009-02-26
US8013016B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
EP2444072A3 (en) Non-mucoadhesive film dosage forms
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
PL1824472T3 (pl) Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii
AU2003249472A1 (en) Use of angelicin and of its structural analogues for the treatment of thalassemia
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
PL372924A1 (en) Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia
CY1107037T1 (el) Χρηση ακετυλ l-καρνιτινης για την παρασκευη ενος φαρμακου για την προληπτικη αγωγη του μετεγχειρητικου πονου
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
PT1937245E (pt) Composto útil para a prevenção e o tratamento de hipertrofia ventricular esquerda em pacientes dialisados
EP1629843A3 (en) Reboxetine for treating chronic fatigue syndrome
HU0200980D0 (enExample)
TW200420560A (en) Crystalline form
WO2006084793A3 (de) Filmtabletten enthaltend ibuprofen-lysinat
AU2002238405A1 (en) Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases